PRL and benign prostatic hyperplasia: To assess the impact of TNF-antagonists on BPH and prostatic inflammation, two mouse models of prostatic enlargement were utilized: a transgenic model with prostate-specific expression of the hormone prolactin (probasin-prolactin [Pb-PRL]) that exhibits prostatic enlargement associated with extensive interstitial inflammation37,38 as well as a spontaneous model of autoimmune inflammation-associated prostatic hyperplastic growth (the NOD mouse)21.